Skip to main content

Stem Cell Therapy for COPD

BOTTOM LINE WHICH WORKS BETTER?

Feature / Study OutcomeWharton’s Jelly MSCs (WJ-MSC)Adipose-Derived MSCs (AD-MSC)
SourceUmbilical cord tissuePatient’s own fat tissue
Route of DeliveryMostly intravenous, some intrabronchialMostly intravenous, some intratracheal
Preclinical Benefit (Animal Models)Strong improvement in alveolar structure, lower inflammationStrong inflammation reduction, improved airflow
Human Safety ProfileExcellent (no major adverse events)Excellent (liposuction minor side effects)
Lung Function Improvement (FEV₁)Minor or no change in short-term studiesMinor or no change in short-term studies
Symptom Improvement (CAT/mMRC)Yes – reduced breathlessness, fewer exacerbationsYes – better walking distance, lower CAT score
Exacerbation ReductionYes (early signs)Yes (anecdotal and early case reports)
Long-term EffectivenessStill under study (Phase II trials ongoing)Still under study (Phase II trials ongoing)
Meta-analysis VerdictSafe, promising for quality of life, more data neededSafe, improves patient comfort, larger trials needed
Summary:
Both Wharton’s jelly stem cells and fat-based stem cells are being tested as treatments for COPD. They’ve been safely used in people, mostly by IV. Early studies show they can reduce symptoms like shortness of breath and flare-ups, but haven’t yet proven they can fix lung function. Lab animals show better results — lungs heal and inflammation drops — but in humans, bigger trials are still needed to say if it really works. So far: safe, promising, not yet a cure.

Written for Nerds /Stem-Cells-for-COPD